We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

BIO-RAD LABORATORIES

Provides full range of instrumentation, reagent kits, software and quality control systems to clinical laboratories. ... read more Featured Products: More products

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Test Detects Cancer Mutations from Circulating DNA

By LabMedica International staff writers
Posted on 30 Aug 2017
Print article
Image: The QX200 Droplet reader for EvaGreen or probe-based digital PCR applications, for use with the QX200 Droplet Digital System (Photo courtesy of Bio-Rad Laboratories).
Image: The QX200 Droplet reader for EvaGreen or probe-based digital PCR applications, for use with the QX200 Droplet Digital System (Photo courtesy of Bio-Rad Laboratories).
In cancer patients, apoptotic and necrotic tumor cells release their DNA content into the blood. This is commonly referred to as circulating tumor DNA (ctDNA); and can be used for DNA sequencing or molecular genotyping assays to identify and quantitatively measure those ctDNA molecules bearing somatic mutations.

The single-color digital polymerase chain (PCR) test offers several advantages over other methods of circulating tumor DNA analysis, compared to next-generation targeted sequencing and fluorescent probe-based digital PCR assays. The main advantage is that the new technique does not rely on pre-amplification, which can introduce errors and biases.

Scientists at Stanford University (Palo Alto, CA) obtained blood samples from patients who had undergone diagnostic cancer gene sequencing of his or her colorectal adenocarcinoma or cholangiocarcinoma and had diagnostic cancer mutation reports available at the time of enrollment into the study. The team used a single-color digital PCR assay that detects and quantifies cancer mutations directly from circulating DNA collected from the plasma of cancer patients. This approach relies on a double-stranded DNA intercalator dye and paired allele-specific DNA primer sets to determine an absolute count of both the mutation and wild-type–bearing DNA molecules present in the sample.

Before Droplet Digital PCR (ddPCR), the cell line and formalin-fixed paraffin-embedded (FFPE) genomic DNA samples were treated with an EcoRI restriction digest, and processed. Patient cell-free DNA did not require enzymatic fragmentation given that these samples are already highly fragmented. All ddPCRs were performed using the Bio-Rad EvaGreen QX200 ddPCR system and protocol. After thermal cycling, the plate was transferred and read by the Bio-Rad QX200 Droplet reader.

The cell-free DNA assay uses an input of 1 ng of non-amplified DNA, approximately 300 genome equivalents, and has a molecular limit of detection of three mutation DNA genome-equivalent molecules per assay reaction. After generation of customized mutation detection assays, the investigators were able to identify tumor-derived circulating DNA from three out of six patients. In one patient, the assay was able to show the presence of three different mutations. The three patients, whose samples did not show elevated cancer DNA, were undergoing active treatment at the time of collection.

Hanlee P. Ji, MD, an Associate Professor and lead investigator of the study said, “Molecular tests like the one we have developed will enable patients to be monitored at every visit, and thus have the potential for quickly tracking cancer growth and spread. Moreover, the test's rapid turnaround and relatively low cost, especially compared to next-generation DNA sequencing, provide a potential opportunity for universal monitoring of more patients than is currently done.” The study was published on August 14, 2017, in The Journal of Molecular Diagnostics.

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.